Genprex (GNPX) said Wednesday that it has signed an exclusive license agreement that grants the company a worldwide, exclusive license for the University of Michigan's patent rights for the Reqorsa gene therapy.
The gene therapy is used in combination with ALK-inhibitors to potentially treat ALK-EML4 positive translocated lung cancer.
Price: 1.23, Change: -0.06, Percent Change: -4.51
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。